TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16697231
Drug: Oral Lactobacillus
Normalized name: Lactobacillus acidophilus Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Lactobacillus rhamnosus GR‐1 (1 x 10(9)) and Lactobacillus reuteri RC‐14 (1 x 10(9))
Study: 8024295
Drug: Budesonide via
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide via Turbuhaler (half the normal dose)
Study: 8024295
Drug: Budesonide via
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide via Nebuhaler (normal dose)
Study: 3501538
Drug: 5-fluorouracil (FUra)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (FUra) plus high-dose continuous-infusion folinic acid
Study: 31255546
Drug: Implant position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant position
Study: 31255546
Drug: Implant material
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant material
Study: 29128208
Drug: Whole pelvic
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole pelvic radiation therapy (WPRT)
Study: 29128208
Drug: Prostate bed
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate bed radiation therapy (PBRT)
Study: 29128208
Drug: No androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No androgen deprivation therapy (No ADT)
Study: 18663341
Drug: Protection cream
Normalized name: PETROLATUM 300 mg in 1 mL TOPICAL CREAM [CUREFINI Skin Protection Cream]
DrugBank: Titanium dioxide (DB09536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protection cream containing antioxidant substances with high radical protection factor
Study: 14511552
Drug: Severe malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe malaria requiring intravenous quinine therapy
Study: 8648387
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy alone
Study: 8648387
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy with mantle or mediastinal RT
Study: 2428795
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy
Study: 29282600
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 28971727
Drug: DSL prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSL prescription
Study: 28971727
Drug: NAL prescription
Normalized name: Foster & Thrive All Day Allergy Original Prescription Strength 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAL prescription
Study: 28971727
Drug: Both DSL
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both DSL and NAL prescriptions
Study: 27496577
Drug: Arthrocentesis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis and BTX‐A injections in the temporal and masseter muscles (Group A)
Study: 27496577
Drug: BTX‐A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A injections in the temporal and masseter muscles only (Group B)
Study: 18505783
Drug: Oral melphalan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melphalan, prednisone, and thalidomide (MPT)
Study: 10537443
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg twice daily)
Study: 10537443
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg twice daily) plus Loviride (100 mg 3 times daily)
Study: 2054076
Drug: GORE-TEX bags
Approvals — FDA: no, EMA: no, PMDA: no
Description: GORE-TEX bags containing silver sulphadiazine cream
Study: 27410169
Drug: Vacuum‐formed co‐polyester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum‐formed co‐polyester oral splints (Group B)
Study: 27410169
Drug: Prefabricated oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefabricated oral splints with water‐filled elastic pads (Group A)
Study: 19860749
Drug: Levobupivacaine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 20 mg (5 mg/ml)
Study: 19860749
Drug: Lidocaine 80
Normalized name: LIDOCAINE 80 mg TOPICAL RING [LidoBand]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 80 mg (20 mg/ml)
Study: 12384409
Drug: Chronic GVHD
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic GVHD treatment
Study: 31064236
Drug: Topical Platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Platelet-rich plasma (PRP) applied twice a day for 12 weeks
Study: 31064236
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and betamethasone for the first 7 days, then hyaluronic acid gel for 12 weeks
Study: 26704712
Drug: Proanthocyanidin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proanthocyanidin (200 mg)
Study: 26704712
Drug: Control (starch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (starch, 200 mg)
Study: 25010702
Drug: Psychosocial Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial Treatment as Usual (TAU)
Study: 19963099
Drug: Temsirolimus 175
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 175 mg for 3 weeks followed by 75 mg once weekly (175/75)
Study: 19581539
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice therapy
Study: 23286772
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine
Study: 11233898
Drug: Preemptive or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive or prophylactic lamivudine treatment (n=10)
Study: 11233898
Drug: Salvage lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Salvage lamivudine treatment after hepatic dysfunction (n=6)
Study: 11233898
Drug: Prophylactic lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prophylactic lamivudine treatment (n=3)
Study: 9780618
Drug: Isosorbide‐5‐mononitrate (IS5MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS5MN) 20 mg bid (8.00 am and 3.00 pm) for 1 week (Group 1)
Study: 9780618
Drug: Isosorbide‐5‐mononitrate (IS5MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS5MN) 40 mg bid (8.00 am and 8.00 pm) for 1 week (Group 2)
Study: 7937663
Drug: multi‐modality therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi‐modality therapy using tuberculin, oliphen plus prednisolone
Study: 3348612
Drug: Cefoperazone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (3 g every 12 h) as a single agent
Study: 3348612
Drug: Sulbactam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam (1.5 g every 12 h) as a single agent
Study: 3348612
Drug: Cefoperazone and
Normalized name: Cefoperazone and sulbactam only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone and sulbactam combination (3/1.5 g)
Study: 25920000
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol (peak BrAC of 40mg/dL)
Study: 25920000
Drug: Moderate-dose alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose alcohol (peak BrAC of 65mg/dL)
Study: 21977941
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 400 mcg once daily in the evening
Study: 21977941
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 200 mcg twice daily
Study: 21977941
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 400 mcg once daily in the morning
Study: 16530911
Drug: Homemade clove
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homemade clove gel
Study: 16530911
Drug: Benzocaine 20%
Normalized name: BENZOCAINE 20% GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine 20% gel
Study: 11014949
Drug: Vasopressin antagonist
Normalized name: Vasopressin antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin antagonist Atosiban (1‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐oxytocin)
Study: 1425870
Drug: Omeprazole (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (240 mg administered in three divided doses over 22 hours)
Study: 1425870
Drug: Normochlorhydria (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normochlorhydria (no omeprazole treatment)
Study: 4085165
Drug: Active pulsed
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pulsed electromagnetic field therapy (PEMF)
Study: 4085165
Drug: Inactive pulsed
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive pulsed electromagnetic field therapy (PEMF)
Study: 10959738
Drug: Inactivated Polio
Normalized name: Inactivated polio vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Polio Vaccine (IPV)
Study: 30512100
Drug: RAS inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitor prescription at hospital discharge
Study: 30512100
Drug: No RAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No RAS inhibitor prescription
Study: 30512100
Drug: RAS inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitor prescription at hospital discharge (stratified by preserved LVEF)
Study: 30512100
Drug: No RAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No RAS inhibitor prescription (stratified by preserved LVEF)
Study: 30512100
Drug: RAS inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitor prescription at hospital discharge (KCCQ score analysis)
Study: 30512100
Drug: No RAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: No RAS inhibitor prescription (KCCQ score analysis)
Study: 22267715
Drug: Vero cell
Normalized name: Vero Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero cell culture-derived influenza vaccine
Study: 19172131
Drug: Glutamine-enriched enteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched enteral nutrition (0.3 g x kg(‐1) x day(‐1))
Study: 10591888
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg/70 kg)
Study: 10591888
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg/70 kg; active drug control)
Study: 11097144
Drug: Scopolamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine administration
Study: 25738849
Drug: Histochemical markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histochemical markers after retinol treatment
Study: 25738849
Drug: Histochemical markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histochemical markers after vehicle treatment
Study: 19494683
Drug: Measures to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measures to help modify the biofilm (including ozone therapy and probiotics)
Study: 19494683
Drug: Measures to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measures to increase enamel resistance to demineralization (including laser treatment of enamel)
Study: 19494683
Drug: Novel 'hybrid'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel 'hybrid' technique for treatment of primary molar caries (Hall technique)
Study: 9834808
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with intravenous piritramide (group P-PCA)
Study: 9834808
Drug: Nurse-administered bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered bolus injections of piritramide (group P-Bolus)
Study: 9834808
Drug: Nurse-administered bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered bolus injections of bupivacaine (group B-Bolus)
Study: 23364953
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg for 48 weeks followed by open-label TDF for an additional 192 weeks
Study: 23364953
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg for 48 weeks followed by open-label TDF for an additional 192 weeks
Study: 21295383
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (SAF) 8 g daily for 16 weeks
Study: 21295383
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 8 g daily for 16 weeks
Study: 17713595
Drug: Follow-up study
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up study after 6 months, n = 25 (combined treatment and placebo)
Study: 15887629
Drug: G 5.0
Normalized name: Glucose 5.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: G 5.0 mg/M 400 mg
Study: 15887629
Drug: G 2.5
Normalized name: Zomig 2.5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: G 2.5 mg/M 400 mg
Study: 15887629
Drug: G 5.0
Normalized name: Glucose 5.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: G 5.0 mg/M 400 mg and G 2.5 mg/M 400 mg
Study: 10904994
Drug: Madden operation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Madden operation + tamoxifen 20 mg OD
Study: 10904994
Drug: Tumorectomy to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumorectomy to disease free margins + tamoxifen 20 mg OD
Study: 9287060
Drug: Topical water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical water and systemic doxycycline, 100 mg for 2 weeks
Study: 9287060
Drug: Topical 0.12%
Normalized name: betamethasone topical 0.12% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.12% chlorhexidine (CHX) and systemic doxycycline, 100 mg for 2 weeks
Study: 9287060
Drug: Topical povidone‐iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical povidone‐iodine and systemic doxycycline, 100 mg for 2 weeks
Study: 9287060
Drug: Topical 0.12%
Normalized name: betamethasone topical 0.12% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.12% CHX and placebo
Study: 9287060
Drug: Topical water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical water and placebo
Study: 3607094
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment program (transcutaneous electrical nerve stimulation)
Study: 18756443
Drug: Early activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early activation (1-2 months post-implant use)
Study: 18756443
Drug: Late activation
Normalized name: Very late activation beta chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late activation (1 year post-implant use)
Study: 18756443
Drug: Control (prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (prior to initial implant activation)
Study: 11916780
Drug: Almitrine infusion
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine infusion at a rate of 8 microg x kg(‐1) x min(‐1) (Group A)
Study: 9699223
Drug: Bioprim tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioprim tablets (80 mg of trimethoprim/400 mg sulfamethoxazole)
Study: 9699223
Drug: Bactrim tablets
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bactrim tablets (80 mg of trimethoprim/400 mg sulfamethoxazole)
Study: 7521788
Drug: 750 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/m2 cyclophosphamide (CHOP)
Study: 7521788
Drug: 1200 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/m2 cyclophosphamide (CHOP)
Study: 7521788
Drug: 1500 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/m2 cyclophosphamide (CHOP)
Study: 4139900
Drug: Modifications in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modifications in treatment planning
Study: 11289747
Drug: Radiotherapy as
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy as part of breast-conserving treatment (BCT) for DCIS
Study: 11289747
Drug: Breast-conserving treatment
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving treatment (BCT) for DCIS without specific mention of control
Study: 8431342
Drug: Alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 20 micrograms kg‐1 and propofol 2.5 mg kg‐1
Study: 29671256
Drug: Routine exogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine exogenous administration of estrogens
Study: 28169916
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E4
Study: 14669843
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol valerate (E2V)
Study: 28267365
Drug: 10, 20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10, 20, or 40 mg E4
Study: 20214694
Drug: Outpatient (OP)
Normalized name: OP-145
DrugBank: OP-145 (DB05672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient (OP) treatment
Study: 20214694
Drug: Inpatient (IP)
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient (IP) treatment
Study: 15025759
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) administered at a constant low dose for up to 6 days
Study: 9142028
Drug: 900 mL
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mL of albumin 5%
Study: 9142028
Drug: 900 mL
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mL of Ringer's solution
Study: 9142028
Drug: 900 mL
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mL of Ringer's acetate solution
Study: 9142028
Drug: 900 mL
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mL blood withdrawal
Study: 8359178
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 10 mg cisapride regimen
Study: 8359178
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 20 mg cisapride regimen
Study: 8359178
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10 mg cisapride regimen
Study: 8359178
Drug: Plasma concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma concentrations of cisapride after 2 x 10 mg
Study: 8359178
Drug: Cisapride plasma
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride plasma concentrations greater than 60 ng.ml‐1
Study: 2820157
Drug: 240 g/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 g/die supplementary mackerel diet, no physical training
Study: 2820157
Drug: Reducing diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reducing diet and a proportion of mackerels of 125 g/d, no physical training
Study: 2820157
Drug: Reducing diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reducing diet and mackerel diet 125 g/d as well as daily swimming training (20 to 30 min)
Study: 27798335
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplements (MMNs)
Study: 27798335
Drug: Fe60F (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe60F (60 mg Fe and 400 μg folic acid)
Study: 27798335
Drug: Fe30F (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe30F (30 mg Fe and 400 μg folic acid)
Study: 25265895
Drug: DPI GSK961081
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPI GSK961081 400 µg + oral placebo
Study: 25265895
Drug: DPI GSK961081
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPI GSK961081 1,200 µg + oral placebo
Study: 25265895
Drug: DPI GSK961081
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPI GSK961081 400 µg + oral propranolol 80 mg
Study: 25265895
Drug: DPI GSK961081
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DPI GSK961081 1,200 µg + oral propranolol 80 mg
Study: 25265895
Drug: DPI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI and oral placebo
Study: 22858074
Drug: Fixed-dose combined
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H)
Study: 14557961
Drug: Clarithromycin (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500-1000 mg), Ethambutol (25 mg/kg), Rifampin (600 mg) 3 times per week
Study: 8990504
Drug: Pure nanocolloid
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure nanocolloid gel
Study: 1333899
Drug: Continuous intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous intra-arterial infusion of 5-FU and lentinan with intermittent epirubicin
Study: 6379275
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic Acid (ASS) 100 mg/day